Evidence map›Paper›PMID 42434295›Full record

ReviewFrontiers in endocrinology2026

The liver-brain axis, from its function to preventive therapeutic strategies in diseases.

Yaoyao Chen, Shangcheng Xu, Tao Sun

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yaoyao ChenCenter for Precision Medicine, School of Medicine and School of Biomedical Sciences, Huaqiao University, Xiamen, China.
Shangcheng XuGeneYoung Biopharmaceuticals, Shenzhen, China.
Tao SunCenter for Precision Medicine, School of Medicine and School of Biomedical Sciences, Huaqiao University, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liver-brain axis (LBA) represents a bidirectional communication network between the liver and the central nervous system (CNS), governed by integrated neural, humoral, and immune signaling pathways. Emerging evidence indicates that the liver functions not merely as a passive metabolic organ subordinate to central commands, but rather as a dynamic hub that actively senses and modulates peripheral neuroimmune responses. We here first delineate the fundamental communication mechanisms and the transport kinetics of signaling molecules governing LBA interactions. We then examine the profound species-specific disparities between humans and mice-particularly regarding signaling mediators, blood-brain barrier (BBB) architecture, and the hepatic immune microenvironment. From a pathophysiological perspective, we establish that LBA dysfunction serves as a core driver of obesity, diabetes, and their multisystemic sequelae, including cardiovascular diseases and psychiatric disorders such as anxiety and depression. Finally, we highlight recent therapeutic advances targeting the LBA for the management of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), atherosclerosis, and associated psychiatric conditions, thereby underscoring the immense clinical potential of LBA-targeted interventions.

Indexed as

BrainLiverLiver DiseasesAnimalsBlood-Brain BarrierHumansObesitySignal Transductioncentral nervous systemdiabetesliver-brain axisobesitypsychiatric disorders

Identifiers

PMID42434295
PMCPMC13349931

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.